- Home
- MIRM vs BKU Comparison
MIRM vs BKU Comparison
Compare MIRM & BKU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- BKU
- Stock Information
- Founded
- MIRM 2018
- BKU 2009
- Country
- MIRM United States
- BKU United States
- Employees
- MIRM N/A
- BKU N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- BKU Savings Institutions
- Sector
- MIRM Health Care
- BKU Finance
- Exchange
- MIRM Nasdaq
- BKU Nasdaq
- Market Cap
- MIRM 3.3B
- BKU 2.8B
- IPO Year
- MIRM 2019
- BKU 2011
- Fundamental
- Price
- MIRM $67.93
- BKU $37.48
- Analyst Decision
- MIRM Strong Buy
- BKU Hold
- Analyst Count
- MIRM 9
- BKU 10
- Target Price
- MIRM $73.89
- BKU $41.60
- AVG Volume (30 Days)
- MIRM 661.2K
- BKU 803.7K
- Earning Date
- MIRM 08-06-2025
- BKU 07-23-2025
- Dividend Yield
- MIRM N/A
- BKU 3.24%
- EPS Growth
- MIRM N/A
- BKU 51.05
- EPS
- MIRM N/A
- BKU 3.41
- Revenue
- MIRM $429,161,000.00
- BKU $999,760,000.00
- Revenue This Year
- MIRM $36.76
- BKU $15.20
- Revenue Next Year
- MIRM $17.48
- BKU $6.43
- P/E Ratio
- MIRM N/A
- BKU $11.23
- Revenue Growth
- MIRM 62.33
- BKU 13.39
- 52 Week Low
- MIRM $36.86
- BKU $28.21
- 52 Week High
- MIRM $69.00
- BKU $44.45
- Technical
- Relative Strength Index (RSI)
- MIRM 82.95
- BKU 54.47
- Support Level
- MIRM $50.25
- BKU $35.34
- Resistance Level
- MIRM $67.45
- BKU $36.27
- Average True Range (ATR)
- MIRM 2.89
- BKU 0.91
- MACD
- MIRM 1.38
- BKU 0.09
- Stochastic Oscillator
- MIRM 94.29
- BKU 72.51
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About BKU BankUnited Inc.
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.